Bioniche granted fast track status for bladder cancer therapy

Mar 05, 2008 (Datamonitor via COMTEX) -- BNHLF | news | PowerRating | PR Charts -- Bioniche Life Sciences has received FDA fast track designation for Urocidin for first-line non-muscle-invasive bladder cancer therapy.

Bioniche plans to start a Phase III clinical trial comparing Urocidin, to the current standard therapy in patients with non-muscle-invasive bladder cancer at high risk of recurrence or progression, later in 2008. The trial aims to demonstrate non-inferior efficacy with respect to disease-free survival and fewer toxicities than the current therapy. The trial, a double-blind and randomized study, will enroll approximately 800 patients in North America, Australia and Europe.

Graeme McRae, president & CEO of Bioniche, said: "This is an important milestone for our Phase III clinical development program with Urocidin. It highlights the need for a safer and more effective therapy for first-line bladder cancer patients."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

Morning Coffee with TradingMarkets -- Free Newsletter

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index